Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, The Netherlands.
Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, The Netherlands.
Mol Oncol. 2021 Nov;15(11):3091-3108. doi: 10.1002/1878-0261.12971. Epub 2021 May 14.
Pancreatic acinar cells have high plasticity and can transdifferentiate into ductal-like cells. This acinar-to-ductal metaplasia (ADM) contributes to tissue maintenance but may also contribute to the premalignant transformation that can eventually progress to pancreatic ductal adenocarcinoma (PDAC). Macrophages are key players in ADM, and macrophage-secreted matrix metalloproteinase (MMP)-9 induces ADM through yet unknown mechanisms. As we previously identified MMP9 as a novel agonist of protease-activated receptor 1 (PAR1), a receptor that is known to orchestrate the cross-talk between macrophages and tumor cells in PDAC, we here assessed the contribution of PAR1 to pancreatic cell fates. We found that genetic deficiency for PAR1 increases acinar gene expression programs in the healthy pancreas and that PAR1 deficiency limits ductal transdifferentiation in experimental systems for ADM. Moreover, PAR1 silencing in PDAC cells increases acinar marker expression. Changes in PDAC cell lines were associated with a downregulation of known Myc-target genes, and Myc inhibition mimics PAR1 deficiency in enhancing acinar programs in healthy organoids and PDAC cells. Overall, we identify the PAR1-Myc axis as a driver of ductal cell fates in premalignant pancreas and PDAC. Moreover, we show that cellular plasticity is not unique to acinar cells and that ductal regeneration into acinar-like cells is possible even in the context of oncogenic KRAS activation.
胰腺腺泡细胞具有较高的可塑性,可以转分化为导管样细胞。这种腺泡到导管的化生(ADM)有助于组织维持,但也可能有助于促进最终发展为胰腺导管腺癌(PDAC)的癌前转化。巨噬细胞是 ADM 的关键参与者,巨噬细胞分泌的基质金属蛋白酶(MMP)-9 通过未知机制诱导 ADM。由于我们之前发现 MMP9 是蛋白酶激活受体 1(PAR1)的一种新型激动剂,PAR1 是一种已知在 PDAC 中协调巨噬细胞和肿瘤细胞之间串扰的受体,因此我们在此评估了 PAR1 对胰腺细胞命运的贡献。我们发现,PAR1 的基因缺失会增加健康胰腺中的腺泡基因表达程序,并且 PAR1 缺失会限制 ADM 实验系统中的导管转化。此外,PDAC 细胞中 PAR1 的沉默会增加腺泡标志物的表达。PDAC 细胞系的变化与已知 Myc 靶基因的下调有关,而 Myc 抑制类似于 PAR1 缺失,可增强健康类器官和 PDAC 细胞中的腺泡程序。总的来说,我们确定了 PAR1-Myc 轴作为癌前胰腺和 PDAC 中导管细胞命运的驱动因素。此外,我们表明,细胞可塑性不仅限于腺泡细胞,即使在致癌 KRAS 激活的情况下,导管也可以再生为腺泡样细胞。